Veterinary Vaccines Market Report 2022-2032

Price	Length	Publisher	Published Date	SKU
from $4,977	444 Pages	Visiongain	February, 2022	VSG17053397

Price	from $4,977
Length	444 Pages
Publisher	Visiongain
Published Date	February, 2022
SKU	VSG17053397

Veterinary Vaccines Market Report 2022-2032

The Veterinary Vaccines Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increase in Zoonotic Diseases

The number, frequency, and variety of zoonotic disease outbreaks have increased dramatically during the last century. These occurrences, which are caused by infections spilling from animal hosts to humans, may have increased by more than thrice in the previous decade, with the incidence of novel zoonotic illnesses infecting humans quadrupling within the same time period. Currently, zoonotic illnesses account for 60% of all new infectious diseases in humans. Animal viruses can infect people directly or indirectly, depending on whether they come into touch with wild or farmed animals. These intermediary hosts function as “mixing vessels,” allowing diseases to evolve genetically and infect humans. And, in recent times, human-to-animal interaction has expanded substantially, increasing the potential of zoonotic disease epidemics. Growing zoonotic diseases has boosted the demand for veterinary vaccines globally.

DNA Vaccine Represents New Frontier In Vaccine Technology

Vaccines based on DNA represent a new frontier in vaccine technology. This technique has a significant use in the veterinary field. DNA vaccines have already made inroads into several areas of veterinary medicine. However, while creating DNA vaccines for animals, numerous critical concerns must be addressed, including whether the vaccine is efficacious and cost effective in comparison to already available alternatives. Another key topic to address is how to utilise this new technology in a variety of scenarios, from the domestic pet to individual fish in fisheries with thousands of animals, to wildlife disease management programmes. In certain situations, DNA vaccines offer an intriguing alternative for immunisation, but in others, the current methods are not enough. A variety of veterinary diseases and the development being made using DNA vaccine technology. Moreover, DNA vaccines can be used for simultaneous immunizations against many pathogens and are relatively less expensive to manufacture and store. Hence, in near future DNA vaccines are expected to witness a significant growth.

What Are These Questions You Should Ask Before Buying A Market Research Report?

How is the veterinary vaccines market evolving?
What is driving and restraining the veterinary vaccines market?
How each veterinary vaccines submarket segment will grow over the forecast period and how much revenue will these submarkets account for in 2032?
How will the market shares for each veterinary vaccines submarket develop from 2022 to 2032?
What will be the main driver for the overall market from 2022 to 2032?
Will leading veterinary vaccines markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
Who are the leading players and what are their prospects over the forecast period?
What are the veterinary vaccines projects for these leading companies?
How will the industry evolve during the period between 2022 and 2032? What are the implication of veterinary vaccines projects taking place now and over the next 10 years?
Is there a greater need for product commercialisation to further scale the veterinary vaccines market?
Where is the veterinary vaccines market heading? And how can you ensure you are at the forefront of the market?
What can be the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path? C-suite?

You need to discover how this will impact the veterinary vaccines market today, and over the next 10 years:

Our 444-page report provides 310 tables and 290 charts/graphs exclusively to you.
The report highlights key lucrative areas in the industry so you can target them – NOW.
Contains in-depth analyse of global, regional and national sales and growth
Highlights for you the key successful trends, changes and revenue projections made by your competitors

This report tells you TODAY how the veterinary vaccines market will develop in the next 10 years, and in-line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal the commercial prospects

In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
You find original analyses, with business outlooks and developments.
Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising veterinary vaccines prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, V, L, W and U are discussed in this report.

Global Veterinary Vaccines Market (COVID Impact Analysis) by Companion Animal

Dogs
Cats

Global Veterinary Vaccines Market (COVID Impact Analysis) by Technology

Live Attenuated Vaccines
Inactivated Vaccines
Toxoid Vaccines
Recombinant Vaccines
Other Technology

Global Veterinary Vaccines Market (COVID Impact Analysis) by Type

Porcine Vaccines
Poultry Vaccine
Livestock Vaccine
Companion Animal Vaccine
Aquaculture Vaccines
Other Type

Global Veterinary Vaccines Market (COVID Impact Analysis) by Livestock

Cattle
Pigs
Poultry
Other Livestock

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 20 leading national markets:

North America Veterinary Vaccines Market, 2022 to 2032 Market Outlook

U.S. Veterinary Vaccines Market, 2022 to 2032 Market Forecast : COVID Impact Analysis
Canada Veterinary Vaccines Market, 2022 to 2032 Market Forecast : COVID Impact Analysis
Mexico Veterinary Vaccines Market, 2022 to 2032 Market Forecast : COVID Impact Analysis

Europe Veterinary Vaccines Market, 2022 to 2032 Market Outlook

Germany Veterinary Vaccines Market, 2022 to 2032 Market Forecast : COVID Impact Analysis
Spain Veterinary Vaccines Market, 2022 to 2032 Market Forecast : COVID Impact Analysis
United Kingdom Veterinary Vaccines Market, 2022 to 2032 Market Forecast : COVID Impact Analysis
France Veterinary Vaccines Market, 2022 to 2032 Market Forecast : COVID Impact Analysis
Italy Veterinary Vaccines Market, 2022 to 2032 Market Forecast : COVID Impact Analysis
Rest of Europe Market Forecast : COVID Impact Analysis

Asia Pacific Veterinary Vaccines Market, 2022 to 2032 Market Outlook

China Veterinary Vaccines Market, 2022 to 2032 Market Forecast : COVID Impact Analysis
Japan Veterinary Vaccines Market, 2022 to 2032 Market Forecast : COVID Impact Analysis
India Veterinary Vaccines Market, 2022 to 2032 Market Forecast : COVID Impact Analysis
Australia Veterinary Vaccines Market, 2022 to 2032 Market Forecast : COVID Impact Analysis
South Korea Veterinary Vaccines Market, 2022 to 2032 Market Forecast : COVID Impact Analysis
Rest of Asia Pacific Market Forecast : COVID Impact Analysis

LAMEA Veterinary Vaccines Market, 2022 to 2032 Market Outlook

Brazil Veterinary Vaccines Market, 2022 to 2032 Market Forecast : COVID Impact Analysis
Turkey Veterinary Vaccines Market, 2022 to 2032 Market Forecast : COVID Impact Analysis
Saudi Arabia Veterinary Vaccines Market, 2022 to 2032 Market Forecast : COVID Impact Analysis
South Africa Veterinary Vaccines Market, 2022 to 2032 Market Forecast : COVID Impact Analysis
UAE Veterinary Vaccines Market, 2022 to 2032 Market Forecast : COVID Impact Analysis
Rest of Latin America, Middle East and Africa

The report also includes profiles and for some of the leading companies in the Veterinary Vaccines Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth

Zoetis Inc.
Virbac Pharmaceutical
Boehringer Ingelheim Animal Health
Elanco Animal Health Incorporated
Intas Pharmaceuticals Ltd
Merck Animal Health
Indian Immunologicals Ltd (IIL)
Phibro Animal Health Corporation (Phibro)
Biogenesis Bago SA
Hester Biosciences
Hipra Pharmaceutical Company

Overall world revenue for Veterinary Vaccines Market, 2022 to 2032 in terms of value the market will surpass US$xx million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Veterinary Vaccines Market, 2022 to 2032 Market report helps you?In summary, our 444+ page report provides you with the following knowledge:

Revenue forecasts for Veterinary Vaccines Market, 2022 to 2032 Market include forecasts for companion animal, technology, type, livestock each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

Revenue forecasts to 2032 for 4 regional and 20 key national markets – See forecasts for the Veterinary Vaccines Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market– including company profiles for 12 of the major companies involved in the Veterinary Vaccines Market, 2022 to 2032 Market.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Veterinary Vaccines Market, 2022 to 2032 Market and leading companies. You will find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.

1 Report Overview: 1.1 Introduction to Veterinary Vaccines Market; 1.2 Global Veterinary Vaccine Market Overview; 1.3 What are the Objectives of this Report?; 1.4 What is the Scope of the Report?; 1.5 Veterinary Vaccines Market Definition; 1.5.1 Vaccination; 1.5.2 Veterinary Vaccines; 1.6 Why You Should Read This Report; 1.7 What This Report Delivers; 1.8 Key Questions Answered By This Analytical Report Include:; 1.9 Who is This Report for?; 1.10 Research Methodology; 1.11 Frequently Asked Questions (FAQs); 1.12 Associated Visiongain Reports; 1.13 About Visiongain
2 Executive Summary: 2.1 Introduction
3 Global Market Dynamics: 3.1 Current Trends in the Global Market; 3.1.1 The Possible Benefits Of Increasing Animal Wellbeing; 3.1.2 New Vaccine Technologies to Combat Outbreak Situations; 3.2 Market Driving Factors; 3.2.1 Growing Interest For The Veterinary Vaccinology Community; 3.2.2 Vaccination For Pet Animals Needs More Attention in Developing countries; 3.2.3 The Increase In Zoonotic Diseases; 3.2.4 Growing demand for Animal derived Protein; 3.3 Market Restraining Factors; 3.3.1 Lack of Immunization Adaptation Among Smallholder Farmers; 3.3.2 The Complexity And Cost Of Vaccine Manufacturing; 3.3.3 Hurdles In The Lengthy And Costly Path To A Licenced Vaccine; 3.4 Opportunities in the Global Market; 3.4.1 DNA Vaccine Represents New Frontier In Vaccine Technology; 3.4.2 Modern Vaccine Strategies in Animal Health; 3.5 Challenges in the Global Market; 3.5.1 Virulent Organisms Are The Most Unambiguous Way To Measure the DOI (Minimum Duration of Immunity); 3.5.2 Highly Advanced Technology, Availability of Skilled labour and Product Recalls Makes Vaccine manufacturing a capital intensive market; 3.5.3 Limited Understanding of Immune Response in Animals; 3.5.4 Regulatory Approval Processes Also Have An Important Impact On The Decision; 3.6 SWOT Analysis for Global Market; 3.7 PEST Analysis for Global Market; 3.8 Porter’s Five Forces; 3.8.1 Threats of New Entrants- Medium; 3.8.2 Bargaining Power of Suppliers- high; 3.8.3 Bargaining Power of Buyers- High to Medium; 3.8.4 Threats of Substitute - Medium; 3.8.5 Rivalry Among The Existing Competitors - High
4 Global Veterinary Vaccines Market Analysis: 4.1 Global Market Outlook; 4.1.1 Global focus on current developments; 4.1.2 Strategies to Increase Adoption Of Animal Vaccines By Smallholder Farmers With Focus On Neglected Diseases And Marginalized Populations; 4.2 Global Market Size Estimation and Forecast by Value; 4.2.1 Pre-COVID-19 Market Scenario; 4.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
5 Global Market Size Estimation and Forecast by Region: 5.1.1 Pre-COVID-19 Market Scenario; 5.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
6 Global Veterinary Vaccines Market by Companion Animal: 6.1.1 Dogs; 6.1.2 Cat; 6.1.3 Pre-COVID-19 Market Scenario; 6.1.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
7 Global Veterinary Vaccines Market by Technology: 7.1.1 Live Attenuated Vaccines; 7.1.2 Inactivated Vaccines; 7.1.3 Toxoid Vaccines; 7.1.4 Recombinant Vaccines; 7.1.5 Other Technology; 7.1.5.1 Attenuated Vaccines; 7.1.5.2 Subunit Vaccines; 7.1.5.3 DNA vaccines; 7.1.5.4 Gene-deleted Vaccines; 7.1.5.5 Virus-vectored Vaccines; 7.1.6 Pre-COVID-19 Market Scenario; 7.1.7 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
8 Global Veterinary Vaccines Market by Type: 8.1.1 Poultry Viral Vaccines; 8.1.2 Porcine Viral Vaccines; 8.1.3 Bovine Viral Vaccines; 8.1.4 Livestock Vaccine; 8.1.5 Companion Animal Vaccine; 8.1.6 Aquaculture Vaccines; 8.1.7 Other Type; 8.1.8 Pre-COVID-19 Market Scenario; 8.1.9 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
9 Global Veterinary Vaccines Market by Livestock: 9.1.1 Cattle; 9.1.2 Poultry; 9.1.3 Fisheries; 9.1.4 Other Livestock; 9.1.5 Pre-COVID-19 Market Scenario; 9.1.6 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10 North America Veterinary Vaccines Market Analysis: 10.1 North America Market Outlook; 10.1.1 Introduction; 10.1.2 Boehringer Ingelheim Animal Health USA Establishes Pawru, Inc.; 10.1.3 The U.S. is Planning Vaccine Bank to Guard against Foot-And-Mouth Disease; 10.1.4 Pre-COVID-19 Market Scenario; 10.1.5 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 10.2 North America Veterinary Vaccines Market Analysis by Country; 10.2.1 Pre-COVID-19 Market Scenario; 10.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 10.3 North America Veterinary Vaccines Market by Companion Animal; 10.3.1 Pre-COVID-19 Market Scenario; 10.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 10.4 North America Veterinary Vaccines Market by Technology; 10.4.1 Pre-COVID-19 Market Scenario; 10.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 10.5 North America Veterinary Vaccines Market by Type; 10.5.1 Pre-COVID-19 Market Scenario; 10.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 10.6 North America Veterinary Vaccines Market by Livestock; 10.6.1 Pre-COVID-19 Market Scenario; 10.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 10.7 US Veterinary Vaccines Market Analysis; 10.7.1 Merck Animal Health Launches Nasalgen®; 10.7.2 Zoetis Expands Vector Vaccine Portfolio With Introduction Of POULVAC® PROCERTA™ HVT-IBD; 10.7.3 Pre-COVID-19 Market Scenario; 10.7.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 10.8 Canada Veterinary Vaccines Market Analysis; 10.8.1 Ingelvac Provenza™ intranasal vaccine for Swine flu; 10.8.2 ERYSENG® PARVO, a new sow reproductive vaccine launched by HIPRA in Canada; 10.8.3 'Time to Vaccinate' Campaign To Empower Farmers With Knowledge; 10.8.4 Pre-COVID-19 Market Scenario; 10.8.5 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 10.9 Mexico Veterinary Vaccines Market Analysis; 10.9.1 Towards a World Free Of Dog-Transmitted Rabies; 10.9.2 3-in-1 Vaccine for Poultry Launched in Mexico; 10.9.3 Pre-COVID-19 Market Scenario; 10.9.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11 Europe Veterinary Vaccines Market Analysis: 11.1 Introduction; 11.1.1 PREVEXXION® RN: the next generation of Marek’s disease vaccines now available in the EU and the UK; 11.1.2 NASYM (by Hipra), the new BRSV strategy has started throughout Europe; 11.1.3 Pre-COVID-19 Market Scenario; 11.1.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 11.2 Europe Veterinary Vaccines Market by Country; 11.2.1 Pre-COVID-19 Market Scenario; 11.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 11.3 Europe Veterinary Vaccines Market by Companion Animal; 11.3.1 Pre-COVID-19 Market Scenario; 11.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 11.4 Europe Veterinary Vaccines Market by Technology; 11.4.1 Pre-COVID-19 Market Scenario; 11.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 11.5 Europe Veterinary Vaccines Market by Type; 11.5.1 Pre-COVID-19 Market Scenario; 11.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 11.6 Europe Veterinary Vaccines Market by Livestock; 11.6.1 Pre-COVID-19 Market Scenario; 11.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 11.7 Germany Veterinary Vaccines Market Analysis; 11.7.1 Canine vaccination in Germany; 11.7.2 Lack of owner compliance and high cost of vaccines are major deterrent for market growth; 11.7.3 Pre-COVID-19 Market Scenario; 11.7.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 11.8 UK Veterinary Vaccines Market Analysis; 11.8.1 BBSRC Under The Auspices Of Global Strategic Alliances; 11.8.2 BBSRC’s (Biotechnology and Biological Sciences Research Council) Current Veterinary Vaccinology Investments; 11.8.3 Pre-COVID-19 Market Scenario; 11.8.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 11.9 France Veterinary Vaccines Market Analysis; 11.9.1 The Main Reason For The Spread Of HPAI Viruses In The South-Eastern Region Of France; 11.9.2 Pre-COVID-19 Market Scenario; 11.9.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 11.10 Italy Veterinary Vaccines Market Analysis; 11.10.1 Vaccination In The Control Strategy Of Bluetongue In Italy; 11.10.2 HIPRA presents ERAVAC®, the new vaccine against RHDV2, in Italy; 11.10.3 Pre-COVID-19 Market Scenario; 11.10.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 11.11 Spain Veterinary Vaccines Market Analysis; 11.11.1 HIPRA presents two new vaccines for poultry farming in Spain; 11.11.2 Pre-COVID-19 Market Scenario; 11.11.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 11.12 Rest of Europe Veterinary Vaccines Market Analysis; 11.12.1 National Legislation Procedures For Poultry Vaccination; 11.12.2 HIPRA launches ICTHIOVAC® VR/PD (vaccine against vibriosis and pasteurellosis in sea bass) in Spain, Italy, Portugal, France and Tunisia; 11.12.3 Pre-COVID-19 Market Scenario; 11.12.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12 Asia-Pacific Veterinary Vaccines Market Analysis: 12.1.1 Introduction; 12.1.2 Rabies Control In South Asia Requires A One Health Approach; 12.1.3 Lack of Awareness of Global Vaccination Practices in Asia; 12.1.4 Pre-COVID-19 Market Scenario; 12.1.5 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.2 Asia-Pacific Veterinary Vaccines Market by Country; 12.2.1 Pre-COVID-19 Market Scenario; 12.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.3 Asia-Pacific Veterinary Vaccines Market by Companion Animal; 12.3.1 Pre-COVID-19 Market Scenario; 12.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.4 Asia-Pacific Veterinary Vaccines Market by Technology; 12.4.1 Pre-COVID-19 Market Scenario; 12.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.5 Asia-Pacific Veterinary Vaccines Market by Type; 12.5.1 Pre-COVID-19 Market Scenario; 12.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.6 Asia-Pacific Veterinary Vaccines Market by Livestock; 12.6.1 Pre-COVID-19 Market Scenario; 12.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.7 China Veterinary Vaccines Market Analysis; 12.7.1 Zoetis to Expand Animal Vaccine Research and Manufacturing in Suzhou, China; 12.7.2 Boehringer Ingelheim Launches First Veterinary Vaccines Produced In China; 12.7.3 Pre-COVID-19 Market Scenario; 12.7.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.8 India Veterinary Vaccines Market Analysis; 12.8.1 Indian Immunologicals Develops Vaccine to Fight Tapeworms in Pigs; 12.8.2 The Vaccine Makers Eyeing US$ 1768.69 Crore Programme; 12.8.3 Pre-COVID-19 Market Scenario; 12.8.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.9 Japan Veterinary Vaccines Market Analysis; 12.9.1 Sumitomo Corporation expands veterinary medicine sales to Indonesia through partnership with Medion Pharma; 12.9.2 Japan Donates Farm Animal Vaccines; 12.9.3 Pre-COVID-19 Market Scenario; 12.9.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.10 South Korea Veterinary Vaccines Market Analysis; 12.10.1 Strategies to Maintain Korea's Animal Rabies Non-Occurrence Status; 12.10.2 Korea has Successfully Implemented A National Rabies Control Program Including Mass Vaccination; 12.10.3 Pre-COVID-19 Market Scenario; 12.10.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.11 Australia Veterinary Vaccines Market Analysis; 12.11.1 In Australia, Over 140 Vaccinations Are Approved For Use In Cattle And Companion Animals; 12.11.2 Pre-COVID-19 Market Scenario; 12.11.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 12.12 Rest of Asia-Pacific Veterinary Vaccines Market Analysis; 12.12.1 Growing awareness of vaccination to boost the market growth for Rest of Asia; 12.12.2 Vietnam: a Sustainable Collaboration with Farmers; 12.12.3 Pre-COVID-19 Market Scenario; 12.12.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13 LAMEA Veterinary Vaccines Market Analysis: 13.1.1 Introduction; 13.1.2 Saudi-Argentine JV Plans $60 Mn Animal Vaccine Manufacturing Plant in Riyadh; 13.1.3 Pre-COVID-19 Market Scenario; 13.1.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.2 LAMEA Veterinary Vaccines Market by Country; 13.2.1 Pre-COVID-19 Market Scenario; 13.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.3 LAMEA Veterinary Vaccines Market by Companion Animal; 13.3.1 Pre-COVID-19 Market Scenario; 13.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.4 LAMEA Veterinary Vaccines Market by Technology; 13.4.1 Pre-COVID-19 Market Scenario; 13.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.5 LAMEA Veterinary Vaccines Market by Type; 13.5.1 Pre-COVID-19 Market Scenario; 13.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.6 LAMEA Veterinary Vaccines Market by Livestock; 13.6.1 Pre-COVID-19 Market Scenario; 13.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.7 Brazil Veterinary Vaccines Market Analysis; 13.7.1 Use Of Collar Impregnated With Insecticide For Reducing Incidence Of Leishmania Infection in Brazil; 13.7.2 Pre-COVID-19 Market Scenario; 13.7.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.8 South Africa Veterinary Vaccines Market Analysis; 13.8.1 Strengthening Veterinary Services in Africa; 13.8.2 Pre-COVID-19 Market Scenario; 13.8.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.9 Saudi Arabia Veterinary Vaccines Market Analysis; 13.9.1 Pre-COVID-19 Market Scenario; 13.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.10 Turkey Veterinary Vaccines Market Analysis; 13.10.1 Turkey: The First Veterinary Vaccine Against Canine Leishmaniosis; 13.10.2 Pre-COVID-19 Market Scenario; 13.10.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.11 UAE Veterinary Vaccines Market Analysis; 13.11.1 Abu Dhabi Campaign Aims To Improve Immunity Among Livestock; 13.11.2 Dubai-Developed Covid-19 Vaccine To Protect Animals Against Virus; 13.11.3 Pre-COVID-19 Market Scenario; 13.11.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis); 13.12 Rest of LAMEA Veterinary Vaccines Market Analysis; 13.12.1 To Increase Productivity Of Small Family Farms In Latin America; 13.12.2 Pre-COVID-19 Market Scenario; 13.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14 Leading Company Profiles: 14.1 Growth Strategy Allows Companies to Expand Their Business; 14.1.1 Growth Through Acquisitions, Expansion and Investment; 14.1.2 Agreements, Contracts and Establishment; 14.1.3 Strategic Alliance; 14.1.4 Introduction of New Segment; 14.2 Zoetis Inc.; 14.2.1 Company Snapshot; 14.2.2 Company Overview; 14.2.3 Company Financial Profile; 14.2.4 Company Product Benchmarking; 14.2.5 Company Recent Developments; 14.3 Virbac Pharmaceutical; 14.3.1 Company Snapshot; 14.3.2 Company Overview; 14.3.3 Company Financial Profile; 14.3.4 Company Product Benchmarking; 14.3.5 Company Recent Developments; 14.4 Boehringer Ingelheim Animal Health; 14.4.1 Company Snapshot; 14.4.2 Company Overview; 14.4.3 Company Financial Profile; 14.4.4 Company Product Benchmarking; 14.4.5 Company Recent Developments; 14.5 Elanco Animal Health Incorporated; 14.5.1 Company Snapshot; 14.5.2 Company Overview; 14.5.3 Company Financial Profile; 14.5.4 Company Product Benchmarking; 14.5.5 Company Recent Developments; 14.6 Intas Pharmaceuticals Ltd; 14.6.1 Company Snapshot; 14.6.2 Company Overview; 14.6.3 Company Financial Profile; 14.6.4 Company Product Benchmarking; 14.6.5 Company Recent Developments; 14.7 Merck Animal Health.; 14.7.1 Company Snapshot; 14.7.2 Company Overview; 14.7.3 Company Financial Profile; 14.7.4 Company Product Benchmarking; 14.7.5 Company Recent Developments; 14.8 Indian Immunologicals Ltd.; 14.8.1 Company Snapshot; 14.8.2 Company Overview; 14.8.3 Company Financial Profile; 14.8.4 Company Product Benchmarking; 14.8.5 Company Recent Developments; 14.9 Phibro Animal Health Corporation; 14.9.1 Company Snapshot; 14.9.2 Company Overview; 14.9.3 Company Financial Profile; 14.9.4 Company Product Benchmarking; 14.9.5 Company Recent Developments; 14.10 Biogenesis Bago SA; 14.10.1 Company Snapshot; 14.10.2 Company Overview; 14.10.3 Company Financial Profile; 14.10.4 Company Product Benchmarking; 14.10.5 Company Recent Developments; 14.11 Hester Biosciences; 14.11.1 Company Snapshot; 14.11.2 Company Overview; 14.11.3 Company Financial Profile; 14.11.4 Company Product Benchmarking; 14.11.5 Company Recent Developments; 14.12 Hipra Pharmaceutical Company; 14.12.1 Company Snapshot; 14.12.2 Company Overview; 14.12.3 Company Financial Profile; 14.12.4 Company Product Benchmarking; 14.12.5 Company Recent Developments
15 Conclusion & Recommendation: 15.1 Conclusion Summary; 15.2 Recommendations; 15.2.1 Duration of Immunity Should Sustain for Longer Duration; 15.2.2 Incessant Vaccine Research will aid in Preventive and Prompt treatment; 15.2.3 Intensive Animal Production To Fulfil Global Nutritional Needs; 15.3 Leading and Fastest Growing Regions
16 Glossary Terms
List of Table: Table 1 Global Veterinary Vaccines Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%)); Table 2 Global Veterinary Vaccines Market Snapshot, 2022 & 2032 (US$million, CAGR %); Table 3 Global Recombinant Viral Vector Vaccines ( Manufacturers & Pathogen); Table 4 Global DNA Vaccines ( Manufacturers & Pathogen); Table 5 Global Recombinant Viral Vector Vaccines ( Manufacturers & Pathogen); Table 6 DIVA Vaccines ( Manufacturers & Pathogen); Table 7 Veterinary Vaccines SWOT Analysis; Table 8 Global Veterinary Vaccines Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%)); Table 9 Global Veterinary Vaccines Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery); Table 10 Global Veterinary Vaccines Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery); Table 11 Global Veterinary Vaccines Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery); Table 12 Global Veterinary Vaccines Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery); Table 13 Global Veterinary Vaccines Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)); Table 14 Global Veterinary Vaccines Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery); Table 15 Global Veterinary Vaccines Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery); Table 16 Global Veterinary Vaccines Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery); Table 17 Global Veterinary Vaccines Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)

Electronic Access - Single User Fulfilled By Publisher:	$4,977
Electronic Access - Departmental 1-5 Users Fulfilled By Publisher:	$5,670
Electronic Access - Global Site License Fulfilled By Publisher:	$8,737
Electronic Access - Site License Fulfilled By Publisher:	$6,930